| Patient | Albert Einstein |
|---|---|
| Date of birth | 1956-03-14 |
| Identifiers | MRN HR-ET012-SYN; SSN (made up) 000-12-6650 |
| Document date | 2026-04-21 |
| Author | Clementine Ward, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Four-week follow-up: CT angiography results and vascular surgery consultation the same day. [S]
Mr. Einstein is a 70-year-old man with a 5.0 cm infrarenal abdominal aortic aneurysm by duplex ultrasound, found and wrapped at a prior exploratory laparotomy, who returns four weeks after his first visit for the CT angiography results and is seen by vascular surgery on the same day. He has had no abdominal, back, or flank pain, fainting, or leg symptoms. He stopped smoking on his quit date a week after the first visit and has had no tobacco for three weeks. He wears the 14 mg patch daily and uses three or four lozenges a day, and he holds an empty, unlit pipe while he works, which he finds helps. He started losartan 50 mg and atorvastatin 40 mg four weeks ago without side effects; his home blood pressure readings average 134/80. The CT angiography two weeks ago showed a 5.2 cm fusiform infrarenal aneurysm with a 2.2 cm neck, calcified atheroma of the aorta and iliac arteries, thickening along the front of the aneurysm from the old wrapping, and no fluid around the aorta. [S]
| Element | Detail |
|---|---|
| Aneurysm | 5.0 cm by ultrasound four weeks ago; 5.2 cm outer-wall diameter on CT angiography two weeks ago |
| Symptoms | None |
| Tobacco | Tobacco-free for three weeks; nicotine patch and lozenges |
| Blood pressure | Home average 134/80 on amlodipine 5 mg and losartan 50 mg |
| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No chest pain, fainting, or leg pain on walking |
| Gastrointestinal | Negative | No abdominal pain |
| Musculoskeletal | Negative | No back pain; no muscle aches on atorvastatin |
| Respiratory | Negative | Morning cough easing since stopping smoking |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Amlodipine 5 mg oral tablet, one tablet daily | One tablet by mouth each morning | Oral route | 2025-05-20 | active | S |
| Losartan 50 mg oral tablet, one tablet daily | One tablet by mouth each morning | Oral route | 2026-03-24 to 2026-04-21 | completed | S |
| Losartan 100 mg oral tablet, one tablet daily | One tablet by mouth each morning | Oral route | 2026-04-21 | active | S |
| Atorvastatin 40 mg oral tablet, one tablet daily | One tablet by mouth each evening | Oral route | 2026-03-24 | active | S |
| Aspirin 81 mg delayed-release oral tablet, one tablet daily | One tablet by mouth daily with food | Oral route | 2026-04-21 | active | S |
| Nicotine 14 mg/24 hour transdermal patch, one patch daily | Apply one new patch each morning | Topical route | 2026-03-24 to 2026-07-14 | completed | S |
| Nicotine 2 mg lozenge as needed for cravings | Dissolve one lozenge in the mouth for a craving, no more often than every 2 hours and no more than 20 a day | Oral route | 2026-03-24 to 2026-09-22 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-04-21 | Body height | 172 | cm | S |
| 2026-04-21 | Body weight | 78.6 | kg | S |
| 2026-04-21 | Body mass index (BMI) [Ratio] | 26.6 | kg/m2 | S |
| 2026-04-21 | Systolic blood pressure | 136 | mm[Hg] | S |
| 2026-04-21 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 2026-04-21 | Heart rate | 70 | /min | S |
| 2026-04-21 | Respiratory rate | 14 | /min | S |
| 2026-04-21 | Body temperature | 36.6 | Cel | S |
| 2026-04-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-04-21 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-04-21 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-04-21 | Creatinine [Mass/volume] in Serum or Plasma | 1.08 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-04-21 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 72 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
Vital signs recorded on 2026-04-21; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 78.6 kg |
| Cardiovascular | Regular rhythm at 70 per minute; blood pressure 136/82 mmHg |
| Abdomen | Pulsatile, non-tender mass above the umbilicus; healed midline scar |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Infrarenal abdominal aortic aneurysm, 5.0 cm by duplex ultrasound, found and wrapped at a prior exploratory laparotomy; under surveillance below the repair threshold | active | confirmed | I71.43 | S — Synthetic modern coding anchored to the documented aneurysm found and wrapped at his exploratory laparotomy; the diameter and all surveillance are synthetic. |
| Essential hypertension | active | confirmed | I10 | S — Synthetic risk factor in the modern frame; no historical blood pressure is documented in the cited sources. |
| Nicotine dependence, pipe tobacco | active | confirmed | F17.290 | S — Synthetic modern coding anchored to his documented pipe smoking. |
| Atherosclerosis of the abdominal aorta, with calcified atheroma on CT angiography | active | confirmed | I70.0 | S — Synthetic finding on the baseline CT angiography. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Aneurysm diameter by duplex ultrasound (CT if views are poor) | Every 6 months at 5.0 to 5.4 cm in men; yearly at 4.0 to 4.9 cm | Up to date | 5.0 cm by duplex ultrasound four weeks ago; next scan due at six months |
| Imaging | CT angiography for baseline anatomy and repair planning | Once at baseline; again when repair is considered | Completed today | CT angiography two weeks ago reviewed: 5.2 cm outer-wall diameter, 2.2 cm neck with 30-degree angulation, calcified atheroma, wrap-related thickening, no periaortic fluid; suitable for endovascular repair if needed |
| Examination | Femoral and popliteal arteries for a coexisting aneurysm | Once at diagnosis | Completed today | Vascular surgery examined the femoral and popliteal arteries: normal pulses, no aneurysm felt; a popliteal duplex will be added to the six-month scan |
| Examination | Aneurysm symptoms and tenderness, with the emergency plan reviewed | Every visit | Completed today | No pain, tenderness, or fainting; emergency plan and wallet card reviewed |
| Referral | Vascular surgery review and shared decision on elective repair | At baseline, then at a threshold change or yearly | Completed today | Seen today by vascular surgery: shared decision on thresholds, surveillance, and endovascular versus open repair recorded |
| Examination | Blood pressure, target below 130/80 | Every visit | Completed today | 136/82 mmHg; above target; losartan increased |
| Self-management | Home blood pressure readings | Before each visit while treatment is being adjusted | Completed today | Home average 134/80 over the past week |
| Laboratory | Metabolic panel (sodium, potassium, creatinine, eGFR) | 2 to 4 weeks after starting or changing losartan; then every 6 months | Completed today | Four weeks after starting losartan: sodium 139, potassium 4.6, creatinine 1.08 mg/dL, eGFR 72; repeat after the dose increase |
| Laboratory | Lipid panel | 4 to 12 weeks after starting a statin; then yearly | Due | Atorvastatin started four weeks ago; lipid panel due by twelve weeks after the start |
| Laboratory | ALT | Once before a statin; then only with symptoms | Up to date | 24 U/L before starting atorvastatin |
| Laboratory | HbA1c | Yearly | Up to date | 5.6 percent four weeks ago |
| Laboratory | Urine albumin-to-creatinine ratio | Yearly | Up to date | 14 mg/g four weeks ago |
| Medication safety | Statin adherence and muscle symptoms | Every visit | Completed today | Taking atorvastatin each evening; no muscle aches |
| Medication safety | Low-dose aspirin: indication and bleeding | Every visit while taking it | Completed today | Started today for aortic atheroma; no history of ulcer or bleeding |
| Medication safety | Medication review: avoid fluoroquinolones and anti-inflammatory pain medicines | Every visit | Completed today | No fluoroquinolone or anti-inflammatory use; told to remind any prescriber about the aneurysm |
| Self-management | Tobacco use and cessation support (5 A's, nicotine replacement) | Every visit | Completed today | Tobacco-free for three weeks; 14 mg patch and three or four lozenges a day |
| Examination | 12-lead ECG | Baseline with hypertension; repeat as indicated | Completed today | 12-lead ECG today, requested by vascular surgery and serving as the hypertension baseline: sinus rhythm at 70, normal intervals, no left ventricular hypertrophy or Q waves |
| Examination | Ankle-brachial index | Every 2 to 3 years at 65 or older or with a smoking history | Due | No ankle-brachial index on record; to be done with the six-month duplex scan |
| Examination | Eye examination for hypertensive retinopathy | Yearly | Due | No eye examination in two years; to be arranged at the wellness visit |
| Examination | Weight and BMI | Every visit | Completed today | 78.6 kg; BMI 26.6 |
Goal progress:
Guideline basis: The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm (2018); 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease (2022); CMID: Clinical Monitoring Intelligence Database, Hypertension and Hyperlipidemia monographs (2026); Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021)
Follow-up: Three-month review with the metabolic panel and home blood pressure readings. Duplex ultrasound at six months. Next scheduled visit 2026-07-14: three-month review: blood pressure, lipids on a statin, and smoking cessation. [S]